Understanding the Role of Targets and Pathways in the Treatment of Non–Small Cell Lung Cancer
This CE/CME/CEU-accredited supplement is jointly provided by
A continuing education activity for nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.
Release date: July 18, 2017 Estimated time to complete activity: 3.0 hour
Expiration date: July 18, 2018
Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Drive, Dinah Shore Bldg. Rancho Mirage, CA 92270
Journal of the Advanced Practitioner in Oncology
94 North Woodhull Road Huntington, NY 11743
© 2017, Annenberg Center for Health Sciences at Eisenhower. All rights reserved.
This supplement is supported by educational grants from Genentech and Merck Sharp & Dohme Corp.
Lisa Cordes, PharmD, BCACP, BCOP, National Institutes of Health
Marianne Davies, DNP, MSN, CNS, ACNP, AOCNP®, Yale University School of Nursing
Beth Eaby-Sandy, MSN, CRNP, OCN®, Abramson Cancer Center, Hospital of the University of Pennsylvania
Clell Hasenbank, PharmD, Providence St Mary Regional Cancer Center
Karen Oishi, MSN, APRN, AGPCNP-BC, OCN®, The University of Texas MD Anderson Cancer Center
Melinda Oliver, BA, BSN, RN, MPAP, The University of Texas MD Anderson Cancer Center
Sandra Cuellar, PharmD, BCOP, University of Illinois Hospital and Health Sciences System—Pharmacy Practice
Samantha Schmidt, PharmD, Lexington Medical Center
Helen Shih, MSN, MPH, University of California, San Francisco Department of Thoracic Oncology
Grashma Vadakkel, PharmD(c), University of South Florida College of Pharmacy
Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, The University of Texas MD Anderson Cancer Center
Activity Rationale and Purpose
Lung cancer is the leading cause of cancer-associated mortality, with 224,390 new cases and 158,080 deaths estimated in 2016 (United States). Lung cancer is histologically divided into small cell lung cancer and NSCLC, which occur in 15% and 85% of lung cancer cases, respectively. The majority of patients present with advanced disease at diagnosis; prognosis is poor, and the 5-year survival rate is 4%, with frequent metastases to bone, liver, and brain. Late diagnosis is a fundamental obstacle to improving outcomes in lung cancer, exacerbating the unmet medical need for APs to maintain a continually high educational status about increasingly complex diagnostics and treatment options for the management of advanced/metastatic NSCLC. This activity will provide education to assist APs in closing or narrowing this medical gap, providing a better understanding of the use of targeted and immunotherapies as they apply to the management of NSCLC.
The activity’s target audience will consist of nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.
After completing this educational activity, participants should be able to:
- Demonstrate an increased understanding of the mechanisms of action of targeted and immunotherapies in the treatment of NSCLC
- Discuss the range of genetic variants in NSCLC and how these are used to select targeted agents for patients with NSCLC
- Interpret a patient’s therapeutic response to immunotherapies to help ensure an optimized outcome
- Identify current diagnosis and treatment paradigms for patients with squamous cell NSCLC
- Identify and manage adverse events that occur with the use of immunotherapies across all subtypes of NSCLC
Statement of Credit—Participants who successfully complete this activity (including the submission of the post-test and evaluation form) will receive a statement of credit.
Physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, Harborside Medical Education, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses. The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. A maximum of 3.0 contact hours may be earned for successful completion of this activity.
Provider approved by the California Board of Registered Nursing, Provider No. 13664, for 3.0 contact hours.
Pharmacists. The knowledge-based accredited educational activity is intended for pharmacists involved in the care of cancer patients. This educational activity is provided by the Annenberg Center for Health Sciences at Eisenhower.
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is assigned ACPE Universal Program #0797-9999-17-064-H01-P. This program is designated for up to 3.0 contact hours (0.3 CEUs) of continuing pharmacy education credit.
All individuals in positions to control the content of this program (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with the ACHS policies and procedures.
Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.
Lisa Cordes, PharmD, BCACP, BCOP, has no potential conflicts of interest to disclose.
Marianne Davies, DNP, MSN, CNS, ACNP, AOCNP®, has served on the speakers’ bureaus for AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck, and has received payments for the development of educational programs for BioMedical Learning Institute, PeerView, and Practicing Physicians Exchange.
Beth Eaby-Sandy, MSN, CRNP, OCN®, has acted as a consultant for ARIAD/Takeda and AbbVie, and has served on speakers’ bureaus for Amgen, AstraZeneca, Helsinn, and Merck.
Clell Hasenbank, PharmD, has no potential conflicts of interest to disclose.
Karen Oishi, MSN, APRN, AGPCNP-BC, OCN®, has no potential conflicts of interest to disclose.
Melinda Oliver, BA, BSN, RN, MPAP, has no potential conflicts of interest to disclose.
Sandra Cuellar, PharmD, BCOP, has received consulting fees or honoraria and served on speakers bureaus for Celgene and Merck.
Samantha Schmidt, PharmD, has no potential conflicts of interest to disclose.
Helen Shih, MSN, MPH, has received consulting fees/honoraria from CE Concepts and Integro Med.
Grashma Vadakkel, PharmD(c), has no potential conflicts of interest to disclose.
Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, has no potential conflicts of interest to disclose.
ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER
John Bayliss, VP, Business Development at the Annenberg Center for Health Sciences at Eisenhower, spouse is an employee of Amgen, Inc; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.
LEAD NURSE PLANNER
Dorothy Caputo, MA, BSN, RN, has nothing to disclose.
Jeannine Coronna has nothing to disclose.
Claudine Kiffer has nothing to disclose.
Patti McLafferty has nothing to disclose.
Lynn Rubin has nothing to disclose.
Pamela Hallquist Viale, RN, MS, CNS, ANP, has nothing to disclose.
Annie Yueh has nothing to disclose.
Moshe Ornstein, MD, MA, has nothing to disclose.
Kimberly D. Allman, CNP, has received consulting or honoraria fees from Exelixis, and has served on speakers’ bureaus for Exelixis, Pfizer, and Sanofi.
This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Annenberg Center for Health Sciences at Eisenhower educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.
The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Annenberg Center for Health Sciences at Eisenhower of any specific therapeutics or approaches to diagnosis or patient management.
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.
How to Earn Credit
To access the learning assessment and evaluation form online, visit https://education.annenberg.net/ptplung
Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.
- 3.00 ACPE
- 3.00 AMA PRA Category 1 Credit(s)™
- 3.00 Attendance
- 3.00 CA-BRN
- 3.00 ANCC